Cover Image
市場調查報告書

全球癌症生物標記市場:預測

Global Cancer Biomarker Market Research Report - Forecast to 2023

出版商 Market Research Future 商品編碼 636598
出版日期 內容資訊 英文 144 Pages
訂單完成後即時交付
價格
Back to Top
全球癌症生物標記市場:預測 Global Cancer Biomarker Market Research Report - Forecast to 2023
出版日期: 2018年02月05日 內容資訊: 英文 144 Pages
簡介

本報告提供全球癌症生物標記市場相關調查分析,市場動態,市場要素分析,各市場區隔的市場分析,競爭情形,主要企業等系統性資訊。

第1章 序文

第2章 簡介

第3章 調查手法

第4章 市場動態

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題
  • 宏觀經濟指標
  • 技術趨勢與評估

第5章 市場要素分析

  • 波特的五力分析
  • 價值鏈分析
  • 投資可行性分析
  • 價格分析

第6章 全球癌症生物標記市場:各類型

  • 簡介
  • 蛋白質生物標記
  • 遺傳基因生物標記
  • 其他

第7章 全球癌症生物標記市場:各用途

  • 簡介
  • 診斷
  • 預後
  • 治療

第8章 全球癌症生物標記市場:各終端用戶

  • 製藥、生物科技企業
  • 診斷工具企業
  • 醫療IT/巨量資料企業
  • 臨床檢驗室

第9章 全球癌症生物標記市場:各地區

  • 簡介
  • 南北美洲
  • 歐洲
  • 亞太地區
  • 中東、非洲

第10章 企業形勢

  • 簡介
  • 市場佔有率分析
  • 主要的發展與策略

第11章 企業簡介

  • F. Hoffmann-La Roche AG
  • Becton Dickinson
  • Abbott Laboratories
  • PerkinElmer, Inc.
  • Bristol-Myers Squibb
  • Bio-Rad Laboratories
  • Eli Lilly and Company
  • Merck & Co., Inc
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • QIAGEN N.V
  • Novartis AG
  • Thermo Fisher Scientific Inc.
  • Illumina Inc.

第12章 結論

第13章 附錄

目錄

Introduction

Most healthcare professionals use diagnostic tests to clarify and support their clinical decision making. Cancer biomarkers are substances or processes that indicate the presence of cancers in the human body. Biomarkers may be produced naturally by the affected tissue or by immune cells in the body in response to cancer. Biomarkers are found in the blood, stool, urine, tumor tissue, bodily fluids, or other tissues. Mostly, they improve cancer detection and facilitate high-speed non-invasive diagnosis using genomics and proteomics. The factors incorporate comprehension of disease procedure and shed light about the uniqueness of an individual's tumor at the molecular level. These components are reflected in the changing outline of clinical trials.

The increasing preference for targeted therapies for the treatment of patients suffering from different types of malignant cancers is one of the major factors driving the growth of the market. Pharmaceutical and biotech companies are increasingly focusing on the use of biomarkers in their drug discovery and development process. The strategic alliances =for biomarker applications in large-stage clinical trials are fueling the growth of this market.

The global cancer biomarker market is segmented on the basis of type, application, and end-user.

Based on biomarker type, the market is further segmented into proteomic and genetic biomarkers.

Based on application, the market is segmented into diagnostic, prognostic, and therapeutic. Based on diagnostic the market is further segmented into imaging and no-imaging.

On the basis of end-user, the market is segmented into pharma and biotech companies, diagnostic tool companies, healthcare IT/big data companies, and clinical laboratories.

The global cancer biomarker market was at USD 10,754.0 million in 2016 and is expected to register a CAGR of 15.8 % during the forecast period.

Key Players

F. Hoffmann-La Roche AG (Switzerland), Becton, Dickinson and Company (U.S.), Abbott Laboratories (U.S.), Merck & Co., Inc.(U.S.), GlaxoSmithKline plc (U.K), Novartis AG (Switzerland), PerkinElmer, Inc (U.S.), Bristol-Myers Squibb (U.S.), Bio-Rad Laboratories (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc (U.S.), QIAGEN N.V (Germany), Thermo Fisher Scientific Inc (U.S.), Illumina Inc (U.S.), and others.

Study objectives

To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global cancer biomarker market.

  • To provide insights into factors influencing and affecting the market growth
  • To provide historical and forecast revenue of market segments and sub-segments with respect to countries
  • To provide strategic profiling of key players in the market, and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
  • To provide economic factors that influence the global cancer biomarker market
  • To provide a detailed analysis of the value chain and supply chain of the global cancer biomarker market

Target Audience

  • Pharmaceutical Companies
  • Medical Devices Companies
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors

Key Findings

  • The global cancer biomarker market is expected to reach USD 29,923.5 million by 2023 at a CAGR of 15.8% from 2017 to 2023
  • On the basis of type, protein biomarker type commanded the largest market share of 41.8% in 2016
  • On the basis of application, the diagnostic segment is expected to command the largest market share of 45.7% over the review period and is also expected to grow at the fastest CAGR of 16.2% during the forecast period, 2017 to 2023
  • The Americas holds the largest share of the global cancer biomarker market which is expected to reach USD 11,736.5 million by 2023
  • Asia Pacific is the fastest growing market, which is expected to grow at a CAGR of 16.5 % over the forecast period

The report also covers the regional analysis

  • Americas
    • North America
  • U.S.
  • Canada
    • South America
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Republic of Korea
    • Rest of Asia Pacific
  • The Middle East & Africa
    • United Arab Emirates
    • Saudi Arabia
    • Oman
    • Qatar
    • Kuwait
    • Rest of Middle East & Africa

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

  • 2.1 Definition
  • 2.2 Scope of the Study
    • 2.2.1 Research Objective
    • 2.2.2 Assumptions
    • 2.2.3 Limitations

Chapter 3. Research Methodology

  • 3.1 Introduction
  • 3.2 Primary Research
  • 3.3 Secondary research
  • 3.4 Market Size Estimation

Chapter 4. Market Dynamics

  • 4.1 Drivers
  • 4.2 Restrains
  • 4.3 Opportunities
  • 4.4 Challenges
  • 4.5 Macroeconomic Indicators
  • 4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

  • 5.1 Porter's Five Forces Analysis
    • 5.1.1 Bargaining Power of Suppliers
    • 5.1.2 Bargaining Power of Buyers
    • 5.1.3 Threat of New Entrants
    • 5.1.4 Threat of Substitutes
    • 5.1.5 Intensity of Rivalry
  • 5.2 Value Chain Analysis
  • 5.3 Investment Feasibility Analysis
  • 5.4 Pricing Analysis

Chapter 6 Global Cancer Biomarker Market, By Types

  • 6.1 Introduction
  • 6.2 Protein Biomarker
  • 6.3 Genetic Biomarker
  • 6.4 Others

Chapter 7 Global Cancer Biomarker Market, By Application

  • 7.1 Introduction
  • 7.2 Diagnostic
    • 7.2.1 Imaging
    • 7.2.2 Non- Imaging
  • 7.3 Prognostic
  • 7.4 Therapeutic

Chapter 8 Global Cancer Biomarker Market, By End Users

  • 8.1 Introduction
  • 8.2 Pharma & Biotech Companies
  • 8.3 Diagnostic Tool Companies
  • 8.4 Healthcare IT/Big Data Companies
  • 8.5 Clinical Laboratories

Chapter 9. Global Cancer Biomarker Market, by Region

  • 9.1 Introduction
  • 9.2 America
    • 9.2.1 North America
      • 9.2.1.1 US
      • 9.2.1.1 Canada
    • 9.2.2 South America
  • 9.3 Europe
    • 9.3.1 Western Europe
      • 9.3.1.1 Germany
      • 9.3.1.2 France
      • 9.3.1.3 Italy
      • 9.3.1.4 Spain
      • 9.3.1.5 U.K
      • 9.3.1.6 Rest of Western Europe
    • 9.3.2 Eastern Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 Republic of Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 The Middle East & Africa
    • 9.5.1 United Arab Emirates
    • 9.5.2 Saudi Arabia
    • 9.5.3 Oman
    • 9.5.4 Kuwait
    • 9.5.5 Qatar
    • 9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

  • 10.1 Introduction
  • 10.2 Market Share Analysis
  • 10.3 Key Development & Strategies
    • 10.3.1 Key Developments

Chapter 11 Company Profiles

  • 11.1 F. Hoffmann-La Roche AG
    • 11.1.1 Company Overview
    • 11.1.2 Financials
    • 11.1.3 Products
    • 11.1.4 Strategy
    • 11.1.5 Key Developments
  • 11.2 Becton Dickinson
    • 11.2.1 Company Overview
    • 11.2.2 Financials
    • 11.2.3 Products
    • 11.2.4 Strategy
    • 11.2.5 Key Developments
  • 11.3 Abbott Laboratories
    • 11.3.1 Company Overview
    • 11.3.2 Financials
    • 11.3.3 Products
    • 11.3.4 Strategy
    • 11.3.5 Key Developments
  • 11.4 PerkinElmer, Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Financials
    • 11.4.3 Products
    • 11.4.4 Strategy
    • 11.4.5 Key Developments
  • 11.5 Bristol-Myers Squibb
    • 11.5.1 Company Overview
    • 11.5.2 Financials
    • 11.5.3 Products
    • 11.5.4 Strategy
    • 11.5.5 Key Developments
  • 11.6 Bio-Rad Laboratories
    • 11.6.1 Company Overview
    • 11.6.2 Financials
    • 11.6.3 Products
    • 11.6.4 Strategy
    • 11.6.5 Key Developments
  • 11.7 Eli Lilly and Company
    • 11.7.1 Company Overview
    • 11.7.2 Financials
    • 11.7.3 Products
    • 11.7.4 Strategy
    • 11.7.5 Key Developments
  • 11.8 Merck & Co., Inc
    • 11.8.1 Company Overview
    • 11.8.2 Financials
    • 11.8.3 Products
    • 11.8.4 Strategy
    • 11.8.5 Key Developments
  • 11.9 Pfizer Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Financials
    • 11.9.3 Products
    • 11.9.4 Strategy
    • 11.9.5 Key Developments
  • 11.10 GlaxoSmithKline plc.
    • 11.10.1 Company Overview
    • 11.10.2 Financials
    • 11.10.3 Products
    • 11.10.4 Strategy
    • 11.10.5 Key Developments
  • 11.11 QIAGEN N.V
    • 11.11.1 Company Overview
    • 11.11.2 Financials
    • 11.11.3 Products
    • 11.11.4 Strategy
    • 11.11.5 Key Developments

 11.12 Novartis AG

    • 11.12.1 Company Overview
    • 11.12.2 Financials
    • 11.12.3 Products
    • 11.12.4 Strategy
    • 11.12.5 Key Developments
  • 11.13 Thermo Fisher Scientific Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Financials
    • 11.13.3 Products
    • 11.13.4 Strategy
    • 11.13.5 Key Developments
  • 11.14 Illumina Inc.
    • 11.14.1 Company Overview
    • 11.14.2 Financials
    • 11.14.3 Products
    • 11.14.4 Strategy
    • 11.14.5 Key Developments
  • 11.15 Others

Chapter 12 MRFR Conclusion

  • 12.1 Key Findings
    • 12.1.1 From CEO's View Point
    • 12.1.2 Unmet Needs of the Market
  • 12.2 Key Companies to Watch
  • 12.3 Prediction of Medical End Users Industry

Chapter 13 Appendix

List of Tables

  • TABLE 1 Cancer Biomarker Industry Synopsis, 2017 - 2023
  • TABLE 2 Global Cancer Biomarker Market Estimates and Forecast, 2017 - 2023, (USD Million)
  • TABLE 3 Global Cancer Biomarker Market by Region, 2017 - 2023, (USD Million)
  • TABLE 4 Global Cancer Biomarker Market by Type, 2017 - 2023, (USD Million)
  • TABLE 5 Global Cancer Biomarker Market by Application, 2017 - 2023, (USD Million)
  • TABLE 6 Global Cancer Biomarker Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 7 North America Cancer Biomarker Market by Type, 2017 - 2023, (USD Million)
  • TABLE 8 North America Cancer Biomarker Market by Application, 2017 - 2023, (USD Million)
  • TABLE 9 North America Cancer Biomarker Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 10 US Cancer Biomarker Market by Type, 2017 - 2023, (USD Million)
  • TABLE 11 US Cancer Biomarker Market by Application, 2017 - 2023, (USD Million)
  • TABLE 12 US Cancer Biomarker Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 13 Canada Market by Type, 2017 - 2023, (USD Million)
  • TABLE 14 Canada Cancer Biomarker Market by Application, 2017 - 2023, (USD Million)
  • TABLE 15 Canada Cancer Biomarker Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 16 South America Cancer Biomarker Market by Type, 2017 - 2023, (USD Million)
  • TABLE 17 South America Cancer Biomarker Market by Application, 2017 - 2023, (USD Million)
  • TABLE 18 South America Cancer Biomarker Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 19 Europe Cancer Biomarker Market by Type, 2017 - 2023, (USD Million)
  • TABLE 20 Europe Cancer Biomarker Market by Application, 2017 - 2023, (USD Million)
  • TABLE 21 Europe Cancer Biomarker Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 22 Western Europe Cancer Biomarker Market by Type, 2017 - 2023, (USD Million)
  • TABLE 23 Western Europe Cancer Biomarker Market by Application, 2017 - 2023, (USD Million)
  • TABLE 24 Western Europe Cancer Biomarker Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 25 Eastern Europe Cancer Biomarker Market by Type, 2017 - 2023, (USD Million)
  • TABLE 26 Eastern Europe Cancer Biomarker Market by Application, 2017 - 2023, (USD Million)
  • TABLE 27 Eastern Europe Cancer Biomarker Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 28 Asia Pacific Cancer Biomarker Market by Type, 2017 - 2023, (USD Million)
  • TABLE 29 Asia Pacific Cancer Biomarker Market by Application, 2017 - 2023, (USD Million)
  • TABLE 30 Asia Pacific Cancer Biomarker Market by End Users, 2017 - 2023, (USD Million)
  • TABLE 31 Middle East & Africa Cancer Biomarker Market by Type, 2017 - 2023, (USD Million)
  • TABLE 32 Middle East & Africa Cancer Biomarker Market by Application, 2017 - 2023, (USD Million)
  • TABLE 33 Middle East & Africa Cancer Biomarker Market by End Users, 2017 - 2023, (USD Million)

List of Figures

  • FIGURE 1 Research Process
  • FIGURE 2 Segmentation for Global Cancer Biomarker Market
  • FIGURE 3 Segmentation Market Dynamics for Global Cancer Biomarker Market
  • FIGURE 4 Global Cancer Biomarker market Share, by Type 2016
  • FIGURE 5 Global Cancer Biomarker market Share, by Application 2016
  • FIGURE 6 Global Cancer Biomarker Market Share, by End Users, 2016
  • FIGURE 7 Global Cancer Biomarker Market Share, by Region, 2016
  • FIGURE 8 North America Cancer Biomarker Market Share, by Country, 2016
  • FIGURE 9 Europe Cancer Biomarker Market Share, by Country, 2016
  • FIGURE 10 Asia Pacific Cancer Biomarker Market Share, by Country, 2016
  • FIGURE 11 Middle East & Africa Cancer Biomarker Market Share, by Country, 2016
  • FIGURE 12 Global Cancer Biomarker Market: Company Share Analysis, 2016 (%)
  • FIGURE 13 F. Hoffmann-La Roche AG: Key Financials
  • FIGURE 14 F. Hoffmann-La Roche AG: Segmental Revenue
  • FIGURE 15 F. Hoffmann-La Roche AG: Geographical Revenue
  • FIGURE 16 Becton Dickinson: Key Financials
  • FIGURE 17 Becton Dickinson: Segmental Revenue
  • FIGURE 18 Becton Dickinson: Geographical Revenue
  • FIGURE 19 Abbott Laboratories: Key Financials
  • FIGURE 20 Abbott Laboratories: Segmental Revenue
  • FIGURE 21 Abbott Laboratories: Geographical Revenue
  • FIGURE 22 PerkinElmer, Inc.: Key Financials
  • FIGURE 23 PerkinElmer, Inc.: Segmental Revenue
  • FIGURE 24 PerkinElmer, Inc.: Geographical Revenue
  • FIGURE 25 Bristol-Myers Squibb: Key Financials
  • FIGURE 26 Bristol-Myers Squibb: Segmental Revenue
  • FIGURE 27 Bristol-Myers Squibb: Geographical Revenue
  • FIGURE 28 Bio-Rad Laboratories: Key Financials
  • FIGURE 29 Bio-Rad Laboratories: Segmental Revenue
  • FIGURE 30 Bio-Rad Laboratories: Geographical Revenue
  • FIGURE 31 Bio-Rad Laboratories: Key Financials
  • FIGURE 33 F. Hoffmann-La Roche AG: Key Financials
  • FIGURE 34 F. Hoffmann-La Roche AG: Segmental Revenue
  • FIGURE 35 F. Hoffmann-La Roche AG: Geographical Revenue
  • FIGURE 36 Becton Dickinson: Key Financials
  • FIGURE 37 Becton Dickinson: Segmental Revenue
  • FIGURE 38 Becton Dickinson: Geographical Revenue
  • FIGURE 39 Abbott Laboratories: Key Financials
  • FIGURE 40 Abbott Laboratories: Segmental Revenue
  • FIGURE 41 Abbott Laboratories: Geographical Revenue
  • FIGURE 42 PerkinElmer, Inc.: Key Financials
  • FIGURE 43 PerkinElmer, Inc.: Segmental Revenue
  • FIGURE 44 PerkinElmer, Inc.: Geographical Revenue
  • FIGURE 45 Bristol-Myers Squibb: Key Financials
  • FIGURE 46 Bristol-Myers Squibb: Segmental Revenue
  • FIGURE 47 Bristol-Myers Squibb: Geographical Revenue
  • FIGURE 48 Bio-Rad Laboratories: Key Financials
  • FIGURE 49 Bio-Rad Laboratories: Segmental Revenue
  • FIGURE 50 Bio-Rad Laboratories: Geographical Revenue
  • FIGURE 51 Eli Lilly and Company: Key Financials
  • FIGURE 52 Eli Lilly and Company: Segmental Revenue
  • FIGURE 53 Eli Lilly and Company: Geographical Revenue
  • FIGURE 54 Merck & Co., Inc.: Key Financials
  • FIGURE 55 Merck & Co., Inc.: Segmental Revenue
  • FIGURE 56 Merck & Co., Inc.: Geographical Revenue
  • FIGURE 57 Pfizer Inc.: Key Financials
  • FIGURE 58 Pfizer Inc.: Segmental Revenue
  • FIGURE 59 Pfizer Inc.: Geographical Revenue
  • FIGURE 60 GlaxoSmithKline plc: Key Financials
  • FIGURE 61 GlaxoSmithKline plc: Segmental Revenue
  • FIGURE 62 GlaxoSmithKline plc: Geographical Revenue
  • FIGURE 63 QIAGEN N.V: Key Financials
  • FIGURE 64 QIAGEN N.V: Segmental Revenue
  • FIGURE 65 QIAGEN N.V: Geographical Revenue
  • FIGURE 66 Novartis AG: Key Financials
  • FIGURE 67 Novartis AG: Segmental Revenue
  • FIGURE 68 Novartis AG: Geographical Revenue
  • FIGURE 69 Thermo Fisher Scientific Inc.: Key Financials
  • FIGURE 70 Thermo Fisher Scientific Inc.: Segmental Revenue
  • FIGURE 71 Thermo Fisher Scientific Inc.: Geographical Revenue
  • FIGURE 72 Illumina Inc.: Key Financials
  • FIGURE 73 Illumina Inc.: Segmental Revenue
  • FIGURE 74 Illumina Inc.: Geographical Revenue
Back to Top